EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinician-Based Functional Scoring and Genomic Insights for Prognostic Stratification in Wolf–Hirschhorn Syndrome

Julián Nevado iD, Raquel Blanco-Lago, Cristina Bel-Fenellós iD, Adolfo Hernández iD, María A Mori-Álvarez, Chantal Biencinto-López iD, Ignacio Málaga iD, Harry Pachajoa iD, Elena Mansilla iD, Fe A García-Santiago iD, Pilar Barrúz, Jair A Tenorio-Castaño iD und 3 weitere

Genes · 2025

DOI: 10.3390/genes16070820 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Genes, 2025. Verfasst von Julián Nevado und 14 weiteren Autor:innen. Beteiligte Einrichtung: Instituto de Genética Médica y Molecular (INGEMM)-IdiPAZ, Hospital Universitario La Paz, 28046 Madrid, Spain. Hauptthemen laut MEDLINE: Wolf-Hirschhorn Syndrome. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: INSTITUTO DE SALUD CARLOS III and FIBHULP, ISCIII (Ministry of Health of Spain), European Union.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Wolf–Hirschhorn syndrome (WHS; OMIM #194190) is a rare neurodevelopmental disorder, caused by deletions in the distal short arm of chromosome 4. It is characterized by developmental delay, epilepsy, intellectual disability, and distinctive facial dysmorphism. Clinical presentation varies widely, complicating prognosis and individualized care.

Methods

We assembled a cohort of 140 individuals with genetically confirmed WHS from Spain and Latin-America, and developed and validated a multidimensional, Clinician-Reported Outcome Assessment (ClinRO) based on the Global Functional Assessment of the Patient (GFAP), derived from standardized clinical questionnaires and weighted by HPO (Human Phenotype Ontology) term frequencies. The GFAP score quantitatively captures key functional domains in WHS, including neurodevelopment, epilepsy, comorbidities, and age-corrected developmental milestones (selected based on clinical experience and disease burden).

Results

Higher GFAP scores are associated with worse clinical outcomes. GFAP showed strong correlations with deletion size, presence of additional genomic rearrangements, sex, and epilepsy severity. Ward’s clustering and discriminant analyses confirmed GFAP’s discriminative power, classifying over 90% of patients into clinically meaningful groups with different prognoses.

Conclusions

Our findings support GFAP as a robust, WHS-specific ClinRO that may aid in stratification, prognosis, and clinical management. This tool may also serve future interventional studies as a standardized outcome measure. Beyond its clinical utility, GFAP also revealed substantial social implications. This underscores the broader socioeconomic burden of WHS and the potential value of GFAP in identifying high-support families that may benefit from targeted resources and services.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Wolf-Hirschhorn SyndromeHumansMaleFemalePrognosisChildChild, PreschoolAdolescentGenomicsInfantAdultPhenotypeYoung AdultEpilepsyChromosomes, Human, Pair 4

Stichwörter der Autor:innen

4p16.3COAWolf–Hirschhorn syndromedevelopmental delayepilepsyfunctional assessment

Autor:innen und Institutionen

  • Instituto de Genética Médica y Molecular (INGEMM)-IdiPAZ, Hospital Universitario La Paz, 28046 Madrid, Spain.
  • CIBERER, Centro de Investigación Biomédica en Red de Enfermedades Raras, ISCIII, 28046 Madrid, Spain.
  • ITHACA-European Reference Network-Hospital La Paz, 28046 Madrid, Spain.
  • Facultad HM de Ciencias de la Salud, Universidad Camilo José Cela e Instituto de Investigación Sanitaria HM Hospitales, 28015 Madrid, Spain.
  • Servicio de Neuropediatría, Hospital Universitario Central de Asturias (HUCA), 33011 Oviedo, Spain.
  • Departamento de Investigación y Psicología en Educación, Facultad de Educación, Universidad Complutense de Madrid, 28040 Madrid, Spain.

ORCID-Profile: Julián Nevado, Cristina Bel-Fenellós, Adolfo Hernández, Chantal Biencinto-López, Ignacio Málaga, Harry Pachajoa, Elena Mansilla, Fe A García-Santiago, Jair A Tenorio-Castaño, Isabel Vallcorba, Pablo Lapunzina

Förderung

  • INSTITUTO DE SALUD CARLOS III and FIBHULP
  • ISCIII (Ministry of Health of Spain)
  • European Union
  • FIBHULP

Zitieren

APA

Nevado, J., Blanco-Lago, R., Bel-Fenellós, C., Hernández, A., Mori-Álvarez, M. A., Biencinto-López, C., Málaga, I., Pachajoa, H., Mansilla, E., García-Santiago, F. A., Barrúz, P., Tenorio-Castaño, J. A., Muñoz-GªPorrero, Y., Vallcorba, I., & Lapunzina, P. (2025). Clinician-Based Functional Scoring and Genomic Insights for Prognostic Stratification in Wolf–Hirschhorn Syndrome. Genes. https://doi.org/10.3390/genes16070820

Vancouver

Nevado J, Blanco-Lago R, Bel-Fenellós C, Hernández A, Mori-Álvarez MA, Biencinto-López C, et al. Clinician-Based Functional Scoring and Genomic Insights for Prognostic Stratification in Wolf–Hirschhorn Syndrome. Genes. 2025. doi:10.3390/genes16070820

BibTeX
@article{Nevado2025,
  author = {Nevado, Julián and Blanco-Lago, Raquel and Bel-Fenellós, Cristina and Hernández, Adolfo and Mori-Álvarez, María A and Biencinto-López, Chantal and Málaga, Ignacio and Pachajoa, Harry and Mansilla, Elena and García-Santiago, Fe A and Barrúz, Pilar and Tenorio-Castaño, Jair A and Muñoz-GªPorrero, Yolanda and Vallcorba, Isabel and Lapunzina, Pablo},
  title = {Clinician-Based Functional Scoring and Genomic Insights for Prognostic Stratification in Wolf–Hirschhorn Syndrome},
  journal = {Genes},
  year = {2025},
  doi = {10.3390/genes16070820}
}
Kostenlos starten →